FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB | Real-time Bid/Ask 13:17:04 14/06/2024 BST | ||
| 35.91 EUR / 37.72 EUR | +24.84% |
|
| Current month | -46.30% | ||
| 1 month | +51.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 36.48 | +23.70% |
| 13/06/24 | 29.49 | +5.81% |
| 12/06/24 | 27.87 | -11.61% |
| 11/06/24 | 31.53 | -16.83% |
| 10/06/24 | 37.91 | -3.34% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 12:57 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SN7D2T |
| ISIN | DE000SN7D2T5 |
| Date issued | 28/07/2022 |
| Strike | 73.59 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.24 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 58 € |
|---|---|
| Lowest since issue | 1.46 € |
| Spread | 1.81 € |
| Spread % | 4.72% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.48
USD
Average target price
53.19
USD
Spread / Average Target
+28.24%
- Stock Market
- Certificates
- Certificat
